Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

WIMMlogo-justsquare

Doug Higgs (WIMM) and Peter Donnelly (WTCHG) have been awarded a collaborative Wellcome Trust Strategic grant (~£3M) to develop a systematic approach to understanding the biology underpinning GWAS hits.  Our aim is to establish a pipeline for identifying causative SNPs and the genes they regulate.  Initially we will study red cell traits (with David Roberts and Dominic Kwiatowski), type 2 diabetes (with Mark McCarthy and Anna Gloyn) and multiple sclerosis (with Lars Fugger and Calli Dendrou).  The pipelines for analysing RNA expression, chromatin modifications,  and chromosme conformation capture will be developed by Doug Higgs, Anna Gloyn and Jim Hughes and we intend that these will ultimately be generally available to others studying human genetic and epigenetic diseases in the WIMM.  Tudor Fulga and Tatjana Sauka Spengler will help develop the tools for genome editing of primary cells and iPS lines (from Zam Cader).  High end statistical genetics and computational biology will be undertaken by Peter Donnelly and Gil McVean.  Hopefully this will be an exciting new venture for the WIMM.

Similar stories

35 Years of the MRC WIMM

In 1989, Sir David Weatherall founded the Institute of Molecular Medicine to bridge the gap between basic science and clinical medicine. To mark 35 years since the MRC WIMM opened its labs, we're looking back on some of our highlights and achievements.